These findings suggest that the tumor microenvironment may modulate the expression of ABCB1 differently than it does in cultured cells or that other compensatory mechanisms, such as ubiquitin-proteasomal degradation of ABCB137, may occur in vivo. The gene discussed is ABCB1; the disease is neoplasm.